Sarah joined Plexus Ventures in 2022 as a Scientific Analyst.

Sarah is a French pharmacist, PharmD, and she holds a master’s degree in the Management of Pharmaceutical Industry and Medical Technology and in Human Biology.

Through her pharma studies, she has been able to understand the different aspects of the development of a drug, from R&D to commercialization without missing the patient perspective. She obtained her thesis thanks to her work in the laboratory of neurochemistry of the Groupement Hospitalier Est, in Lyon focusing on a protein, the TDP53, responsible of two neurodegenerative diseases: ALS and FTD.

She is now part of Plexus Ventures as a scientific analyst and is a core team member working on different projects including aspects of innovative therapies, biosimilars, immuno-oncology treatment.